Actelion Pharmaceuticals Ltd, Drug Discovery and Preclinical Research & Development, Gewerbestrasse 16, CH-4123 Allschwil, Switzerland.
Bioorg Med Chem Lett. 2010 Mar 1;20(5):1539-42. doi: 10.1016/j.bmcl.2010.01.070. Epub 2010 Jan 22.
A novel series of dual orexin receptor antagonists was prepared by heteroaromatic five-membered ring system replacement of the dimethoxyphenyl moiety contained in the tetrahydroisoquinoline core skeleton of almorexant. Thus, replacement of the dimethoxyphenyl by a substituted pyrazole and additional optimization of the substitution pattern of the phenethyl motif allowed the identification of potent antagonists with low nanomolar affinity for hOX(1)R and hOX(2)R. The synthesis and structure-activity relationship of these novel antagonists will be discussed in this communication. These investigations furnished several suitable candidates for further evaluation in in vivo studies in rats.
通过用噻唑杂环五员环系统取代阿莫雷克斯的四氢异喹啉核心骨架中含有的二甲氧基苯基部分,制备了一系列新型的双重食欲素受体拮抗剂。因此,通过用取代的吡唑替换二甲氧基苯基,并且对苯乙基结构的取代模式进行进一步优化,确定了具有低纳摩尔亲和力的 hOX(1)R 和 hOX(2)R 的强效拮抗剂。本通讯将讨论这些新型拮抗剂的合成和构效关系。这些研究为进一步在大鼠体内研究中进行评估提供了几个合适的候选物。